Skip to main content
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
50.20
-1.50 (-2.90%)
Apr 29, 2026, 4:08 PM HKT

HKG:2315 Revenue

Biocytogen Pharmaceuticals (Beijing) had revenue of 433.06M CNY in the quarter ending March 31, 2026, with 39.48% growth. This brings the company's revenue in the last twelve months to 1.56B, up 43.92% year-over-year. In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B with 40.63% growth.

Revenue (ttm)
1.56B CNY
Revenue Growth
+43.92%
P/S Ratio
23.47
Revenue / Employee
1.08M CNY
Employees
1,443
Market Cap
41.68B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.38B398.35M40.63%
Dec 31, 2024980.45M263.54M36.76%
Dec 31, 2023716.91M183.03M34.28%
Dec 31, 2022533.88M179.33M50.58%
Dec 31, 2021354.56M101.01M39.84%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Shanghai Henlius Biotech 7.42B
Shanghai Junshi Biosciences 2.78B
3SBio 19.69B
Genscript Biotech 7.47B
InnoCare Pharma 2.87B
RemeGen 3.62B
Duality Biotherapeutics 2.06B
Shanghai Bao Pharmaceuticals 54.70M
Revenue Rankings

Biocytogen Pharmaceuticals (Beijing) News

More News